CAR T
Published on February 11, 2025
Safety and efficacy of odronextamab in R/R DLBCL post-CAR T-cell therapy
by Blood
Topp MS, Matasar MJ, Allan JN, et al. Odronextamab Monotherapy in R/R DLBCL After Progression With CAR T-Cell Therapy: Primary Analysis of the ELM-1 study. Blood. 2024; (doi: 10.1182/blood.2024027044).
Research suggests odronextamab is beneficial for individuals with relapsed/refractory diffuse large B-cell lymphoma whose condition worsens after chimeric antigen receptor T-cell (CAR T) therapy. As part of the ELM-1 study, researchers followed 60 post-CAR T patients who received weekly infusions of the CD20xCD3 bispecific antibody for four cycles, followed by maintenance doses, until disease progression. Within 90 days of CAR-T treatment, 48.3% of participants relapsed. Investigators observed the objective response rate to odronextamab of 48.3%, lasting a median 14.8 months. Median duration of response was not reached in the 31.7% of participants who achieved complete response. Promising efficacy outcomes — including median progression-free survival of 4.8 months and median overall survival of 10.2 months — were accompanied by an acceptable safety profile. Just 12 of the patients (20%) experienced infections of Grade 3 or higher, and there were no cases of immune effector cell-associated neurotoxicity syndrome. The most common treatment-emergent adverse event, affecting 48.3% of the sample, was cytokine release syndrome — no cases of which were classified as high-grade.
Read More
![]()